Turkish Journal of Medical Sciences
Volume 51

Number 5

Article 11

1-1-2021

A novel marker of systemic inflammation in psoriasis and related
comorbidities: chitotriosidase
BİLAL İLANBEY
ÖMER FARUK ELMAS
ESER YILDIRIM SÖZMEN
ÜMRAN GÜNAY
ABDULLAH DEMİRBAŞ

See next page for additional authors

Follow this and additional works at: https://journals.tubitak.gov.tr/medical
Part of the Medical Sciences Commons

Recommended Citation
İLANBEY, BİLAL; ELMAS, ÖMER FARUK; SÖZMEN, ESER YILDIRIM; GÜNAY, ÜMRAN; DEMİRBAŞ,
ABDULLAH; ATASOY, MUSTAFA; TÜRSEN, ÜMİT; and LOTTİ, TORELLO (2021) "A novel marker of systemic
inflammation in psoriasis and related comorbidities: chitotriosidase," Turkish Journal of Medical
Sciences: Vol. 51: No. 5, Article 11. https://doi.org/10.3906/sag-2101-137
Available at: https://journals.tubitak.gov.tr/medical/vol51/iss5/11

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

A novel marker of systemic inflammation in psoriasis and related comorbidities:
chitotriosidase
Authors
BİLAL İLANBEY, ÖMER FARUK ELMAS, ESER YILDIRIM SÖZMEN, ÜMRAN GÜNAY, ABDULLAH DEMİRBAŞ,
MUSTAFA ATASOY, ÜMİT TÜRSEN, and TORELLO LOTTİ

This article is available in Turkish Journal of Medical Sciences: https://journals.tubitak.gov.tr/medical/vol51/iss5/11

Turkish Journal of Medical Sciences
http://journals.tubitak.gov.tr/medical

Research Article

Turk J Med Sci
(2021) 45: 2318-2323
© TÜBİTAK
doi: 10.3906/sag-2101-137

A novel marker of systemic inflammation in psoriasis and related comorbidities:
chitotriosidase
Bilal İLANBEY 1

, Ömer Faruk ELMAS 2 , Eser Yıldırım SÖZMEN 3 , Ümran GÜNAY 4 , Abdullah DEMİRBAŞ 5,* ,
Mustafa ATASOY 6 , Ümit TÜRSEN 7 , Torello LOTTİ 8
1Department of Medical Biochemistry, Faculty of Medicine, Ahi Evran University, Kırşehir, Turkey
2Department of Dermatology, Faculty of Medicine, Kırıkkale University, Kırıkkale,Turkey
3Department of Medical Biochemistry, Faculty of Medicine, Ege University, İzmir,Turkey
4Department of Dermatology, İstanbul Dr. Lütfi Kırdar City Hospital, İstanbul,Turkey
5Department of Dermatology, Evliya Çelebi Training and Research Hospital, Kütahya Health Sciences University, Kütahya, Turkey
6Department of Dermatology, Kayseri City Hospital, Health Science University, Kayseri, Turkey
7Department of Dermatology, Faculty of Medicine, Mersin University, Mersin,Turkey
8Department of Dermatology, Faculty of Medicine, Guglielmo Marconi University, Rome, Italy
Received: 12.01.2021

Accepted/Published Online: 03.04.2021

Final Version: 21.10.2021

Background/aim: Chitotriosidase (ChT) is an enzyme secreted by activated macrophages and neutrophils in response to
proinflammatory signals. There is growing evidence indicating that ChT activity reflects the systemic inflammatory status. This study
aimed to investigate whether serum ChT activity increased in patients with psoriasis and related comorbidities.
Materials and methods: This cross-sectional study included 53 (28 with associated comorbidities and 25 without comorbidities)
patients with psoriasis and 52 healthy volunteers. All participants underwent laboratory investigations for serum ChT levels, complete
blood count, erythrocyte sedimentation rate, C-reactive protein, and serum lipid levels.
Results: The patients with psoriasis showed significantly higher levels of ChT activity as compared to the healthy controls (23.5 ±
11.4 vs. 17.5 ± 10.4 μmol/mL/hour; p = 0.015). Additionally, the ChT activity was significantly higher in patients with comorbidities
than in those without (p = 0.042).
Conclusion: Our data support the pathogenetic role of inflammatory processes induced by macrophage activation in patients with
psoriasis and related comorbidities. We believe that high ChT activity in patients with psoriasis may serve as an early prediction of the
possible related comorbidities.
Keywords: Chitotriosidase, comorbidity, macrophage, psoriasis

1. Introduction
Psoriasis is a relatively common chronic inflammatory
cutaneous disease characterized by epidermal
hyperproliferation. It is considered an immune-mediated
inflammatory disorder in which the T lymphocytes,
dendritic cells, and cytokines play crucial roles.
Multisystem chronic inflammation in psoriasis can be
associated with multiple comorbidities, including obesity,
metabolic syndrome, and cardiovascular diseases [1–3].
Although the exact etiology remains unknown, there are
various suggested risk factors for psoriasis. Genetic
predisposition is a fundamental factor, and smoking,
obesity, and alcohol use are well-known risk factors.
Drugs and infections have also been described as
triggering factors for psoriasis [1,4].
Chitotriosidase (ChT) is an enzyme secreted by
activated macrophages and neutrophils in response to
proinflammatory signals. Currently, it is used as a
biochemical marker for the diagnosis and monitoring of
lysosomal storage diseases [5–7]. Studies have reported
high activities of ChT in a wide range of diseases such as

atherosclerosis, malaria, bronchial asthma, sarcoidosis,
non-alcoholic steatohepatitis, diabetes mellitus (DM),
Alzheimer’s disease, cancer, and thalassemia [8–12]. High
ChT activity is reportedly associated with a high risk of
cardiovascular events [13]. There is growing evidence
indicating that ChT activity reflects the inflammatory
status. Furthermore, it has been reported that ChT plays a
vital role in the immune response against chitincontaining pathogens [14]. ChT is produced after at least
7 days of cell culture and increases with time; hence, it is
considered a chronic inflammatory marker rather than an
acute-phase reactant [15].
In this study, we aimed to investigate whether ChT
could serve as a marker for the prediction of
comorbidities in patients with psoriasis, which is a
common chronic inflammatory skin disease.
2. Materials and methods
This cross-sectional study, which was carried out between
March and September 2020, included 53 patients with
clinically and histopathologically confirmed psoriasis (28
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with associated comorbidities and 25 without
comorbidities) and 52 healthy volunteers. All procedures
were in accordance with the principles of the Declaration
of Helsinki, and the study was approved by the local
clinical research ethics committee (approval date and
number: 2020-02/16). Written informed consent was
obtained from all participants.
Pregnant or breastfeeding females, patients under 18
years of age, those undergoing systemic treatment, and
those with accompanying infections or malignancies were
excluded. Patients who had received topical treatment or
phototherapy within the last month or systemic treatment
within the last 3 months were also excluded.
All participants underwent physical examination and
laboratory investigations for serum ChT levels, complete
blood count (CBC), erythrocyte sedimentation rate (ESR),
C-reactive protein (CRP), and serum lipid levels.
Additionally, the Psoriasis Area and Severity Index (PASI)
and disease duration were recorded for all the patients.
Psoriasis area and severity index (PASI) score ≤10 was
determined as mild psoriasis, while >10 moderate to
severe psoriasis [16].
A total of 5 mL of venous blood samples from all
participants were obtained in a tube without
anticoagulant and 4 mL in K2EDTA tube of the forearm in
the morning after at least 8–10 h of fasting. Blood
collected in plain tubes was allowed to clot for 30 min and
then centrifuged at 2000 ×g for 10 min. Routine
biochemical tests were immediately performed on some
of the serum, and about 0.5 mL the remaining samples
were stored at −80 ℃ to measure the ChT levels. The CBC
of the blood samples collected in K2EDTA tubes was
evaluated using Sysmex XN1000 (Sysmex Corp., Kobe,
Japan). Routine biochemistry and hormone tests were
performed using Cobas c702 (Roche Diagnostics, Tokyo,
Japan) autoanalyzer system with standard laboratory
methods.

The ChT activity was measured using the method
proposed by Hollak et al. [5]. According to this method,
after thawing frozen serum samples, each serum sample
was incubated with a substrate containing 4methylumbelliferyl-chitotrioside at 37 ℃ for 2 h.
Fluorescence was detected by excitation at 360 nm and
emission at 445 nm (Modulus microplate fluorometer,
Turner Biosystems, Inc., California, USA). The ChT activity
results were represented as μmol/mL/hour.
2.1. Statistical analysis
Statistical package for the Social Sciences software
(version 21.0; IBM Corp., Armonk, NY, USA) was used for
statistical analysis. The conformity of the data to normal
distribution was examined using the Kolmogorov–
Smirnov and Shapiro–Wilk tests. Logarithmic conversion
was performed for non-normally distributed variables.
Normally distributed variables were presented as mean
and standard deviation and non-normally distributed
variables as median and interquartile range. Data were
compared between the two groups using either student’s
t-test (normal distribution) or Mann–Whitney U test (nonnormal distribution). The chi-square test was used to
compare the categorical data. Correlations were assessed
using either the Pearson correlation test for normally
distributed data or Spearman’s P for non-normally
distributed data. One-way analysis of variance was used
to compare the normally distributed variables between
the groups, and the Kruskal–Wallis test was used to
compare non-normally distributed variables. Post-hoc
testing was performed using Tukey’s test. Statistical
significance was set at p-values <0.05.
3. Results
This study included 25 patients without comorbidities (11
males, 14 females), 28 patients with comorbidities (8
males, 20 females), and 52 healthy controls (15 males, 37
females). The demographic characteristics of the
participants are summarized in Table 1.

Table 1. Demographic parameters, Psoriasis Area and Severity Index (PASI) scores, and lipid levels of the participants.
Controls
Patients without comorbidities (n = 25)
Patients with comorbidities (n = 28)
Parameters
(n = 52)
Male/female (n)
15/37
11/14
8/20

p-values
0.437

Age (years)

42.8 ± 13.9

41.6± 15.5

52.3 ± 11.9*¥

0.006

Duration of psoriasis (years)

-

3 (1-18)

3 (1-8)

0.673

PASI

-

6.4 (5-10)

5 (4.1-10)

0.561

18/5

24/6

0.487

136.3 ± 93.5

144.4 ± 71.1*

0.012

PASI ≤10 (n)/PASI >10 (n)
Triglycerides (mg/dL)

100 ± 50.2

Total cholesterol (mg/dL)

160.7 ± 32.2 176.2 ± 40

198.2 ± 37.9*

0.001

HDL-cholesterol (mg/dL)

53.7 ± 12.8

45.7 ± 11.4*

49.4 ± 9.5

0.016

LDL-cholesterol (mg/dL)

89.5 ± 31

101 ± 36.7

124 ± 52.9*

0.006

The values are presented as mean±SD or median (25th and 75th percentiles).
* p < 0.05, compared to the controls (post-hoc Tukey test).
¥ p < 0.05, compared to patients without comorbidities (post-hoc Tukey test).
PASI, Psoriasis Area and Severity Index; HDL, high-density lipoprotein; LDL, low-density lipoprotein
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In this study cohort, 16 patients had psoriatic arthritis
(PsA), 10 had type II DM, 8 had hypertension (HT), and 4
had hypothyroidism. There were no statistically
significant differences between patients with and without
comorbidities in terms of the disease duration and PASI
values (Table 1).
Patients without comorbidities showed significantly
higher CRP levels as compared to the healthy controls (p
= 0.031), but there were no statistically significant
differences in the ChT activity, white blood cell (WBC)
count, or ESR between control and patients without
comorbidities (Table 2).
ChT activity, CRP, and ESR levels were significantly
higher (p = 0.001, p = 0.016, and p = 0.009, respectively)
in patients with comorbidities than in the healthy controls
(Table 2).
All patients showed significant higher ChT activity as
compared to the healthy controls (23.5 ± 11.4 vs. 17.5 ±
10.4 μmol/mL/h; p = 0.015).
Moreover, the ChT activity was significantly higher in
patients with comorbidities than in those without (p =
0.042) (Figure 1); however, there were no statistically
significant differences in the white blood cell (WBC)
count, C-reactive protein (CRP), and erythrocyte
sedimentation rate (ESR) between the two groups (Table
2).
Spearman’s correlation analysis revealed a positive
correlation between the WBC count and PASI scores (rho
= 0.426, p = 0.026) in patients with comorbidities. There
was no correlation between inflammatory parameters
and PASI scores in patients without comorbidities.
Based on the PASI scores, the patients were grouped as
PASI >10 and PASI ≤10. The ChT activity was found to be
significantly lower in patients without comorbidities with
PASI >10 (p = 0.022). The other inflammation parameters
showed no statistically significant differences (Table 3).
The WBC count was significantly lower in patients
with PsA (p = 0.043) than in those without comorbidities.
No inflammatory parameters showed statistically
significant differences between the patients with and
without comorbidities. The ChT activity and CRP levels
were significantly higher in hypertensive patients (p =
0.025 and p = 0.035, respectively) than in patients without
comorbidities (Table 4, Figure 2). No inflammatory
parameters showed statistically significant differences in

patients with hypothyroidism when compared with those
without comorbidities (Table 4).
There was no statistically significant difference in the
lipid levels between patients with and without
comorbidities. Triglycerides, total cholesterol, and lowdensity lipoprotein (LDL) levels were significantly higher
(p = 0.008, p = 0.001, and p = 0.004, respectively) in
patients with comorbidities than in the healthy controls.
However, there were no statistically significant
differences in these parameters between patients without
comorbidities and healthy controls. Notably, the highdensity lipoprotein (HDL) levels were significantly lower
in patients without comorbidities than in the healthy
controls (p = 0.012) (Table 1).
4. Discussion
Recent studies on the pathogenesis of psoriasis have
shown that the disease occurs because of complex
relationships between T lymphocytes, dendritic cells,
macrophages, mast cells, neutrophils, and keratinocytes
[1]. Macrophages are potent phagocytic cells capable of
antigen presentation and secretion of a wide range of
chemical mediators. They are thought to play a key role in
psoriasis by releasing important inflammatory products,
such as tumor necrosis factor (TNF)-α and interleukin

Figure 1. Mean values of the chitotriosidase activity in
patients and controls.

Table 2. Inflammatory parameters of the participants.
Inflammatory markers

Controls (n = 52) Patients without comorbidities (n = 25)

Patients with comorbidities (n=28)

p-value

Chitotriosidase (μmol/mL/h)

17.5 ± 10.4

20.1 ± 8.2

26.5 ± 13.1*¥

0.003

7.6 ± 1.7

7.94 ± 1.89

7.49 ± 2.13

0.636

ESR (mm/h)

6 (5-13)

8 (3-17)

14 (6-19)*

0.032

CRP (mg/L)

1.0 (0.4-1.9)

1.6 (0.9-3.2) *

3.0 (0.9-6.9)*

0.018

WBC

(×109 cells/L)

The values are presented as mean±SD or median (25th and 75th percentiles).
* p < 0.05, compared to the controls.
¥ p < 0.05, compared to the patients without comorbidity.
WBC, white blood cell; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.
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Table 3. Distribution of the inflammatory parameters by PASI scores.
Parameters

Patients without comorbidities (n = 25)

PASI

≤10 (n = 19)

>10 (n = 6)

p-value

≤10 (n = 24)

>10 (n = 4)

p-value

Chitotriosidase (μmol/mL/h)

19.26 ± 7.2

16.5 ± 2.78

0.022

27.5 ± 13.6

19.6 ± 7.0

0.392

WBC (×109 cells/L)

7.5 ± 1.6

8.4 ± 1.7

0.301

7.18 ± 2.0

9.2 ± 2.1

0.078

ESR (mm/h)

1.6 (0.9–2.1)

2 (1.2–2.9)

0.341

2.3 (1.0–6.4)

3.9 (1.1–11.5)

0.792

CRP (mg/L)

6.5 (3–15)

13 (5.5–28)

0.720

14(5.5–20)

12.5(8–23)

0.599

Patients with comorbidities (n = 28)

The values are presented as mean±SD or median (25th and 75th percentiles).
PASI, Psoriasis Area and Severity Index; WBC, white blood cell; ESR, erythrocyte sedimentation rate; CRP, C-reactive
protein.
Table 4. Distribution of the inflammatory parameters by the comorbidities.
Patients without comorbidities (n =
PsA (n = 16)
Inflammatory markers
25)
21 ± 11.5
Chitotriosidase (μmol/mL/h) 20.1 ± 8.2
(p = 0.571)
6.8 ± 1.3
WBC (×109 cells/L)
7.94 ± 1.89
(p = 0.043)*
11 (7–20.5)
ESR (mm/h)
8 (3–15)
(p = 0.112)
2.0 (0.9–6.4)
CRP (mg/L)
1.7 (1.0–3.5)
(p = 0.772)

DM (n = 10) HT (n = 8)

Hypothyroidism (n = 4)

25.3 ± 12.4
(p = 0.156)
7.9 ± 2.8
(p = 0.770)
11 (7-17)
(p = 0.180)
3.0 (1.4–6.4)
(p = 0.167)

26.6 ± 10.4
(p = 0.154)
7.5 ± 2.4
(p = 0.574)
22.5 (13.5–27.5)
(p = 0.051)
3.6 (1.2–7.7)
(p = 0.590)

30.9 ± 15.6
(p = 0.025)*
9.4 ± 2.1
(p = 0.086)
18.5 (11–24.5)
(p = 0.055)
6.2 (2.5-9.2)
(p = 0. 035)*

The values are presented as mean±SD or median (25th and 75th percentiles).
WBC, white blood cell; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; PsA, psoriatic arthritis; DM,
diabetes mellitus; HT, hypertension.
* p < 0.05, compared to the patients without comorbidities.
(IL)-17 [17]. Along with genetic predisposition, chronic
inflammation is responsible for occurrence of
comorbidities, especially in severe forms of psoriasis
[3,18].
ChT, a member of the mammalian chitinase family
(GH18), hydrolyzes chitin in lysosomes. There is growing
evidence that ChT can be used as a marker of
inflammation. Although studies have shown high
activities of ChT in a wide range of diseases, including

Figure 2. Mean values of the chitotriosidase activity for each
comorbidity.
(PsA: psoriatic arthritis, DM: diabetes mellitus, HT:
hypertension).

cardiovascular diseases, DM, and cancer, there are no data
regarding the role of ChT activity in patients with
cutaneous disorders [5–12,19]. To the best of our
knowledge, this is the first study to investigate the
possible role of ChT activity in patients with psoriasis and
related comorbidities. Our study results revealed a
relationship between ChT activity and psoriasis,
especially in patients with comorbidities. The ChT activity,
CRP, and ESR levels were significantly higher in patients
with comorbidities than in healthy controls. However,
only ChT levels were significantly higher in patients with
comorbidities than in those without comorbidities.
Therefore, it can be speculated that ChT may be a marker
for comorbid diseases, but more data are needed in a large
group for evidence.
The PASI is a scoring system used to measure the
severity and extent of psoriasis. To calculate the PASI
score, a representative area of psoriasis is chosen for each
body area affected. The intensity of redness, thickness,
and scaling of the lesion is evaluated as “none,” “mild,”
“moderate,” “severe,” or “very severe.” The three intensity
scores are then added up for each of the four body areas
to obtain the subtotals. Each subtotal is then multiplied by
the body surface area represented by that region [16]. Our
study revealed no correlation between the PASI scores
and ChT activity. The majority of the cases included in our
study were mild cases, and severe cases were in minority.
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This limitation could explain the absence of a statistical
correlation between the PASI scores and ChT activity.
Dyslipidemia is not uncommon in psoriasis [20,21]. In
our study, only HDL cholesterol was found to be lower in
patients without comorbidities when compared with the
healthy controls. The total cholesterol, triglyceride, and
LDL cholesterol levels were higher in patients with
comorbidities than in controls. There was no correlation
between the lipid parameters and ChT activity. No lipid
parameters showed statistically significant differences
between patients with and without comorbidities.
In our study, 16 patients (30.1%) presented PsA. The
prevalence of inflammatory arthritis has been reported to
be 6%–42% in patients with psoriasis [3]. The incidence
of arthritis increases in proportion to the severity and
duration of psoriasis. Early diagnosis of PsA can prevent
joint damage and improve the quality of life [22]. In our
study, ChT activity and other inflammatory parameters
did not differ significantly in patients with psoriatic
arthritis (Table 4).
Psoriasis is associated with an increased risk of DM
and insulin resistance, independent of the traditional risk
factors [3]. Inflammatory mediators secreted by
macrophages, such as IL-6 and TNF-α, have been reported
to cause insulin resistance in psoriasis [23]. Two different
studies reported high ChT activity in patients with DM
[9,24]. Similarly, in our study, ChT activity was higher in
patients with psoriasis and DM than in healthy controls,
but there was no significant difference when compared
with patients without comorbidities. This could be
attributed to the low number of patients with DM (Table
4).
Hypertension is another common comorbidity with
psoriasis. Various proinflammatory cytokines released
from macrophages, such as TNF-α and IL-1β, and
increased reactive oxygen species have been suggested to
play critical roles in the pathogenesis of hypertension
[23,25]. In our study, ChT activity was found to be higher
in patients with hypertension (30.9 ± 15.6
μmol/mL/hour) than in those with other comorbidities
(Table 4). The higher activity of ChT in hypertension
suggests that macrophages may play a greater role in the
pathogenesis of hypertension. No study has investigated
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